

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
01 June 2023 (01.06.2023)



(10) International Publication Number
WO 2023/096577 A2

(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/SG2022/050840

(22) International Filing Date:
18 November 2022 (18.11.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10202113177P 26 November 2021 (26.11.2021) SG

(71) Applicants: **NATIONAL UNIVERSITY OF SINGAPORE** [SG/SG]; 21 Lower Kent Ridge Road, Singapore 119077 (SG). **IMPERIAL COLLEGE INNOVATIONS LIMITED** [GB/GB]; Level 1, Faculty Building, Imperial College London, Exhibition Road, South Kensington, London SW7 2AZ (GB).

(72) Inventors: **WONG, Wei Jie, Garrett**; c/o National University of Singapore, Yong Loo Lin School of Medicine / Dept. of Biochemistry, 21 Lower Kent Ridge Road, Singapore 119077 (SG). **LIM, Li Rong**; c/o National University of Singapore, Yong Loo Lin School of Medicine / Dept. of Biochemistry, 21 Lower Kent Ridge Road, Singapore 119077 (SG). **GO, Maybelle Darlene Kho**; c/o National University of Singapore, Yong Loo Lin School of Medicine / Dept. of Biochemistry, 21 Lower Kent Ridge Road, Singapore 119077 (SG). **YEW, Wen Shan**; c/o National University of Singapore, Yong Loo Lin School of Medicine / Dept. of Biochemistry, 21 Lower Kent Ridge Road, Singapore 119077 (SG). **FREEMONT, Paul S.**; c/o Imperial College London, Faculty of Medicine / Department of Infectious Diseases, Exhibition Road, South Kensington, London SW7 2AZ (GB). **BELL, David John**; c/o Imperial College London, SynbiCITE, iHub, 84 Wood Lane, London W12 0BZ (GB).

(74) Agent: **CHUNG, Jing Yeng**; Marks & Clerk Singapore LLP, Tanjong Pagar Post Office, P.O Box 636, Singapore 910816 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,

NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: PRODUCTION OF D-LYSERGIC ACID

(57) Abstract: The present invention relates to modified cells suitable for use in the production of ergot alkaloids. More particularly, the present invention provides engineered recombinant cells comprising one or more genes that code for one or more enzymes in the biosynthetic pathway from tryptophan to D-lysergic acid (DLA). The present invention also provides methods of culturing said engineered recombinant cells for the production of DLA and other ergot alkaloids.

WO 2023/096577 A2